| 词条 | Draft:Neurotrope |
| 释义 |
{{Infobox company | name = Neurotrope, Inc. | logo = | logo_size = | logo_alt = | logo_caption = | logo_padding = | image = | image_size = | image_alt = | image_caption = | trading_name = | native_name = | native_name_lang = | romanized_name = | former_name = | type = | traded_as = {{Nasdaq|NTRP}} | ISIN = | industry = Biopharmaceutical | genre = | fate = | predecessor = | successor = | founded = 2012 | founder = | defunct = | hq_location = | hq_location_city = | hq_location_country = | num_locations = | num_locations_year = | area_served = | key_people = Dr. Daniel Alkon (President & Chief Science Officer) | products = | brands = | production = | production_year = | services = | revenue = | revenue_year = | operating_income = | income_year = | net_income = | net_income_year = | aum = | assets = | assets_year = | equity = | equity_year = | owner = | members = | members_year = | num_employees = | num_employees_year = | parent = | divisions = | subsid = | module = | ratio = | rating = | website = {{URL|www.neurotropebioscience.com}} | footnotes = | intl = }}Neurotrope, Inc. (also known as Neurotrope BioScience) is an American biopharmaceutical company focused on developing a platform of drugs intended for treating various neurological disorders such as Alzheimer's Disease, Fragile X Syndrome, and Niemann–Pick type C. It is incorporated in Nevada, headquartered in New York City, and is listed on the NASDAQ since 2017. Since its inception in 2012, Neurotrope has primarily worked on developing its lead compound Bryostatin 1, a macrolide lactone believed to have synaptogenic effects according to the company.[1][2] In 2017, Neurotrope completed a Phase 2b trial for Bryostatin 1 in patients suffering from Alzheimer's Disease. Trial results met pre-specified goals and paved the way for further investigation according to the company.[3] The results were met with criticism however, as it was pointed out that the top-line data failed to reach statistical significance according to industry standards.[4][5][6] After tracking the progress of patients for an additional period of time, the company released its post-hoc analysis of the trial several months later, this time showing a statistically significant and sustained improvement in patients receiving Bryostatin 1 versus placebo. An even greater benefit was reported in the sub-group of patients that were not taking Memantine during the trial period, suggesting that Bryostatin 1 may not bring any clinical benefits to patients if they are taking NMDA inhibitors (such as Memantine) at the same time.[7][8] A new confirmatory phase 2 trial is currently ongoing, this time using a larger patient population that is not taking Memantine at the same time, where the company hopes to repeat the results observed in the previous post-hoc analysis with a greater statistical power.[3][7][9][10] References1. ^[https://www.sec.gov/Archives/edgar/data/1513856/000114420418013105/tv487391_10k.htm Annual report for the fiscal year ended December 31, 2017], Neurotrope via SEC Edgar. Retrieved April 3, 2018. 2. ^[https://globenewswire.com/news-release/2017/03/30/947184/0/en/Neurotrope-Inc-Nasdaq-NTRP-to-Ring-The-Nasdaq-Stock-Market-Opening-Bell.html Neurotrope, Inc. (Nasdaq: NTRP) to Ring The Nasdaq Stock Market Opening Bell], NASDAQ via GlobeNewswire. Retrieved February 10, 2018. 3. ^1 [https://www.genengnews.com/gen-articles/the-scoop-alzheimers-drug-tries-to-build-up-a-head-of-steam/6285 The Scoop: Alzheimer’s Drug Tries to Build Up a Head of Steam], Genetic Engineering & Biotechnology News. Retrieved March 31, 2018. 4. ^[https://www.reuters.com/article/us-neurotrope-study/neurotrope-alzheimers-drug-data-fails-to-impress-shares-crater-idUSKBN17X1LB Neurotrope Alzheimer's drug data fails to impress; shares crater], Reuters. Retrieved February 9, 2018. 5. ^Neurotrope: A Shameful PR Stunt, Science Translational Medicine. Retrieved February 10, 2018. 6. ^[https://www.thestreet.com/story/14110638/1/neurotrope-spins-a-failed-alzheimer-s-drug-study.html Neurotrope Spins a Failed Alzheimer's Drug Study], TheStreet.com. Retrieved February 10, 2018. 7. ^1 [https://alzheimersnewstoday.com/2018/08/08/bryostatin-reversed-cognitive-decline-in-moderate-to-severe-alzheimers/ Bryostatin-1 Can Reverse Cognitive Decline in Moderate-to-Severe Alzheimer’s, New Data Shows], Alzheimer’s News Today. Retrieved August 9, 2018. 8. ^[https://alzheimersnewstoday.com/2018/03/21/bryostatin-neurotrope-improves-cognition-advanced-alzheimers/ Bryostatin Improves Cognition in Patients with Advanced Alzheimer’s, Analysis Finds], Alzheimer’s News Today. Retrieved April 10, 2018. 9. ^[https://www.statnews.com/2018/08/15/alzheimers-patients-drug-development-outrage/ As Alzheimer’s drug developers give up on today’s patients, where is the outrage?], Stat News. Retrieved August 16, 2018. 10. ^[https://newyork.legalexaminer.com/health/senior-care/advancements-in-alzheimers-treatment-interview-with-dr-daniel-alkon/ Advancements in Alzheimer’s Treatment: Interview with Dr. Daniel Alkon], The Legal Examiner. Retrieved December 8, 2018. |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。